Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study
Background: Cerebral glioma has a devastating impact on cognitive, physical, social,
psychological and spiritual well-being. We sought to understand the multidimensional experience …
psychological and spiritual well-being. We sought to understand the multidimensional experience …
Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer
SC Erridge, Y Seppenwoolde, SH Muller… - Radiotherapy and …, 2003 - Elsevier
Purpose: To investigate patient set-up, tumor movement and shrinkage during 3D conformal
radiotherapy for non-small cell lung cancer. Materialsandmethods: In 97 patients, electronic …
radiotherapy for non-small cell lung cancer. Materialsandmethods: In 97 patients, electronic …
ESTRO-ACROP guideline “target delineation of glioblastomas”
…, M Brada, AJ Chalmers, SE Combs, SC Erridge… - Radiotherapy and …, 2016 - Elsevier
Background and purpose Target delineation in glioblastoma (GBM) varies substantially
between different institutions and several consensus statements are available. This guideline …
between different institutions and several consensus statements are available. This guideline …
Radiotherapy for pituitary adenomas: long-term efficacy and toxicity
SC Erridge, DS Conkey, D Stockton… - Radiotherapy and …, 2009 - Elsevier
BACKGROUND: Radiotherapy for pituitary adenomas is an effective treatment but remains
controversial due to toxicity concerns. MATERIALS AND METHODS: A retrospective audit of …
controversial due to toxicity concerns. MATERIALS AND METHODS: A retrospective audit of …
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 …
…, B Stea, J Dietrich, K Hopkins, S Erridge… - The Lancet …, 2017 - thelancet.com
Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion
mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet …
mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet …
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study …
Background Cilengitide is a selective αvβ3 and αvβ5 integrin inhibitor. Data from phase 2
trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in …
trials suggest that it has antitumour activity as a single agent in recurrent glioblastoma and in …
[HTML][HTML] Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
…, A Mahajan, CJ Schultz, S Erridge… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care
for newly diagnosed glioblastoma (GBM). O 6-methylguanine-DNA methyltransferase (…
for newly diagnosed glioblastoma (GBM). O 6-methylguanine-DNA methyltransferase (…
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic …
MJ van den Bent, B Baumert, SC Erridge… - The Lancet, 2017 - thelancet.com
… Sara C Erridge … The randomisation schedule was generated with the electronic EORTC
web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the …
web-based ORTA system. Patients were assigned in equal numbers (1:1:1:1), using the …
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
…, JR Perry, D Hyun Nam, SC Erridge… - Neuro …, 2017 - academic.oup.com
Background: Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the
established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This …
established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This …
Mental incapacity in patients undergoing neuro-oncologic treatment: a cross-sectional study
S Kerrigan, S Erridge, I Liaquat, C Graham, R Grant - Neurology, 2014 - AAN Enterprises
Objective: To evaluate the prevalence of mental incapacity to make neuro-oncologic
treatment decisions and to identify patients likely to experience difficulty with medical decision-…
treatment decisions and to identify patients likely to experience difficulty with medical decision-…